Markus J. Barten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Markus J. Barten has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Stefan Dhein
6 shared publicationsJan F. Gummert
5 shared publicationsAttila Tarnok
4 shared publicationsFriedrich W. Mohr
4 shared publicationsHartmuth B. Bittner
4 shared publicationsAxel Rahmel
3 shared publications
Latest Publications
- 31 August 2013
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 19 (8) , S20
Mitral Valve Surgery in Ischemic Heart Failure - A Excellent Surgical Option!
- 31 August 2013
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 19 (8) , S20
Mitral Valve Surgery in Ischemic Heart Failure - A Excellent Surgical Option!
- 1 August 2012
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 18 (8) , S42
Mitral Valve Pathology in Severe Impaired Left Ventricles Can Be Successfully Managed Using the Right Side Minimally Invasive Surgical Approach
- 1 August 2012
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 18 (8) , S42
Mitral Valve Pathology in Severe Impaired Left Ventricles Can Be Successfully Managed Using the Right Side Minimally Invasive Surgical Approach
- 1 March 2012
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 93 (3) , 913-920
Donor Type Impact on Ischemia-Reperfusion Injury After Lung Transplantation
- 1 March 2012
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 93 (3) , 913-920
Donor Type Impact on Ischemia-Reperfusion Injury After Lung Transplantation
- 1 October 2007
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 37 (10) , 1367-1373
Pharmacodynamic monitoring of the immunosuppressive therapy in patients after heart transplantation: Whole blood flow cytometric analysis of lymphocyte function
- 1 October 2007
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 37 (10) , 1367-1373
Pharmacodynamic monitoring of the immunosuppressive therapy in patients after heart transplantation: Whole blood flow cytometric analysis of lymphocyte function
- 15 January 2007
- Published by Wiley in Cell Proliferation
- Vol. 40 (1) , 50-63
Pharmacodynamics of T‐cell function for monitoring immunosuppression
Abstract. Objectives: Recent studies show that measuring pharmacodynamic (PD) effects offers a unique possibility to predict immunosuppression. Thus, in this study we have monitored the PD properties of immunosuppressants on diverse T‐cell functions in heart transplant (HTx) recipients.Materials: PDs and blood concentrations (PK) of three different basis‐immunosuppressive drugs were studied: cyclosporin A (CsA); tacrolimus (TRL) and sirolimus (SRL). T‐cell function was analysed by expression of proliferating cell nuclear antigen (PCNA) labelling, expression of cytokines (IL‐2, IFN‐γ) and surface antigen (for example, CD25) by FACS analysis.Results: In group I, at time points C0 and C2, increased CsA‐PK significantly inhibited expression of IL‐2, IFN‐γ, PCNA and CD25 (P < 0.05). Correlations (r2) at C2 between inhibition of T‐cell functions (PD) with PK and with drug doses were: CsA‐PK: 0.71–0.91 and CsA‐dose: 0.73–0.87. In group II, increased TRL‐PK over time did not further inhibit expression of CD25, but inhibited PCNA expression more on day 3, and IL‐2 and IFN‐γ expression was significantly higher on days 2 and 3 compared to PD effects of CsA (P < 0.05). Blood SRL concentrations in C0 group III, increased on day 1 and remained stable at days 3 and 4. Expression of PCNA was not altered in the SRL‐PK category, whereas expression of CD25 was higher and expression of cytokines was lower than PD effects of CsA.Conclusions: Our results show that PD effects on T‐cell function can be used to monitor immunosuppression bringing potential to increase the efficacy and safety of immunosuppressive therapy after HTx.
- 15 January 2007
- Published by Wiley in Cell Proliferation
- Vol. 40 (1) , 50-63
Pharmacodynamics of T‐cell function for monitoring immunosuppression
Abstract. Objectives: Recent studies show that measuring pharmacodynamic (PD) effects offers a unique possibility to predict immunosuppression. Thus, in this study we have monitored the PD properties of immunosuppressants on diverse T‐cell functions in heart transplant (HTx) recipients.Materials: PDs and blood concentrations (PK) of three different basis‐immunosuppressive drugs were studied: cyclosporin A (CsA); tacrolimus (TRL) and sirolimus (SRL). T‐cell function was analysed by expression of proliferating cell nuclear antigen (PCNA) labelling, expression of cytokines (IL‐2, IFN‐γ) and surface antigen (for example, CD25) by FACS analysis.Results: In group I, at time points C0 and C2, increased CsA‐PK significantly inhibited expression of IL‐2, IFN‐γ, PCNA and CD25 (P < 0.05). Correlations (r2) at C2 between inhibition of T‐cell functions (PD) with PK and with drug doses were: CsA‐PK: 0.71–0.91 and CsA‐dose: 0.73–0.87. In group II, increased TRL‐PK over time did not further inhibit expression of CD25, but inhibited PCNA expression more on day 3, and IL‐2 and IFN‐γ expression was significantly higher on days 2 and 3 compared to PD effects of CsA (P < 0.05). Blood SRL concentrations in C0 group III, increased on day 1 and remained stable at days 3 and 4. Expression of PCNA was not altered in the SRL‐PK category, whereas expression of CD25 was higher and expression of cytokines was lower than PD effects of CsA.Conclusions: Our results show that PD effects on T‐cell function can be used to monitor immunosuppression bringing potential to increase the efficacy and safety of immunosuppressive therapy after HTx.
- 1 December 2006
- Published by Elsevier in International Immunopharmacology
- Vol. 6 (13-14) , 2011-2017
Affects of immunosuppression on circulating dendritic cells: An adjunct to therapeutic drug monitoring after heart transplantation
- 1 December 2006
- Published by Elsevier in International Immunopharmacology
- Vol. 6 (13-14) , 2011-2017
Affects of immunosuppression on circulating dendritic cells: An adjunct to therapeutic drug monitoring after heart transplantation
- Open Access
- 14 February 2006
- Published by Wiley in Cytometry Part A
- Vol. 69A (3) , 105-108
Novel aspects of systems biology and clinical cytomics
- 14 February 2006
- Published by Wiley in Cytometry Part A
- Vol. 69A (3) , 105-108
Open AccessNovel aspects of systems biology and clinical cytomics
- Open Access
- 14 February 2006
- Published by Wiley in Cytometry Part A
- Vol. 69A (3) , 155-157
Cytokine analysis to predict immunosuppression
Background: Recently, it has been realized that TH1/TH2 cytokine production offer the unique possibility to predict drug efficacy. However, there is still an incessant need to explore assay conditions and techniques of analyzing cytokines, which are specific and reliable for monitoring drug efficacy.Methods: In this study we used the multiplex bead array technique to detect cytokines of TH1/TH2 cells in whole blood of heart transplanted (HTx) recipients.Results: We found significantly different levels of cytokine expression in HTx recipients compared with cytokine levels in patients prior to HTx. Furthermore, particular cytokine levels were significantly decreased 2 h after drug dosing, compared with cytokine levels before dosing in mitogen‐stimulated whole blood.Conclusions: Cytokine analysis with the multiplex array technique in mitogen‐stimulated whole blood provides the possibility to predict immunosuppression. © 2006 International Society for Analytical Cytology
- 14 February 2006
- Published by Wiley in Cytometry Part A
- Vol. 69A (3) , 155-157
Open AccessCytokine analysis to predict immunosuppression
Background: Recently, it has been realized that TH1/TH2 cytokine production offer the unique possibility to predict drug efficacy. However, there is still an incessant need to explore assay conditions and techniques of analyzing cytokines, which are specific and reliable for monitoring drug efficacy.Methods: In this study we used the multiplex bead array technique to detect cytokines of TH1/TH2 cells in whole blood of heart transplanted (HTx) recipients.Results: We found significantly different levels of cytokine expression in HTx recipients compared with cytokine levels in patients prior to HTx. Furthermore, particular cytokine levels were significantly decreased 2 h after drug dosing, compared with cytokine levels before dosing in mitogen‐stimulated whole blood.Conclusions: Cytokine analysis with the multiplex array technique in mitogen‐stimulated whole blood provides the possibility to predict immunosuppression. © 2006 International Society for Analytical Cytology
- 1 December 2005
- Published by Elsevier in Transplantation Proceedings
- Vol. 37 (10) , 4532-4534
Pharmacodynamic Monitoring of the Conversion of Cyclosporine to Tacrolimus in Heart and Lung Transplant Recipients
- 1 December 2005
- Published by Elsevier in Transplantation Proceedings
- Vol. 37 (10) , 4532-4534
Pharmacodynamic Monitoring of the Conversion of Cyclosporine to Tacrolimus in Heart and Lung Transplant Recipients
- 1 April 2005
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 27 (2) , 123-131
Mycophenolic Acid Interaction With Cyclosporine and Tacrolimus In Vitro and In Vivo
The effect of mycophenolic acid (MPA) in combination with either cyclosporine (CsA) or tacrolimus (TRL) on whole-blood lymphocyte function was assessed in vitro as well as in vivo. For the in vitro studies, rat whole blood was incubated with different concentrations of MPA together with CsA or TRL. In vivo, rats (n = 6 per group) were orally treated with 2.5 or 5 mg/kg of mycophenolate mofetil (MMF), either alone or in combination with 5 mg/kg CsA or 4 mg/kg TRL. Blood was obtained before and at different times after dosing. For both in vitro and in vivo studies, mitogen-stimulated whole blood was analyzed by flow cytometry to determine inhibition of expression of lymphocyte proliferation (proliferating cell nuclear antigen, PCNA) and T-cell activation (eg, CD25). Plasma MPA concentrations were measured by HPLC, and whole-blood CsA and TRL concentrations were quantified using LC-MS/MS. In vitro, low concentrations of 250 and 500 nM MPA acted additively with CsA and overadditively with TRL to suppress lymphocyte function, whereas higher MPA concentrations (1000 nM) in these combinations did not further increase inhibition compared with monotherapy with CsA or TRL alone. In vivo, the MPA AUC0-24 showed a dose-dependent increase. CsA and TRL AUC0-24 were not influenced by the MMF dose. Combination therapy increased inhibition of lymphocyte function compared with MMF monotherapy with a pronounced effect on PCNA compared with CD25. Significant differences between 2.5 and 5 mg/kg MMF in the combination groups were observed at 2 or 6 hours after dosing because of the maximal inhibitory effect on PCNA and CD25 expression (P < 0.05, ANOVA). However, in combination with TRL no different effects on the inhibition of CD25 expression were found between the 2 MMF doses. These novel data indicate that measurement of pharmacodynamic parameters of lymphocyte function in whole blood may help to monitor drug combination therapy and provide a rationale for drug reduction to minimize toxicity without compromising efficacy.
- 1 April 2005
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 27 (2) , 123-131
Mycophenolic Acid Interaction With Cyclosporine and Tacrolimus In Vitro and In Vivo
The effect of mycophenolic acid (MPA) in combination with either cyclosporine (CsA) or tacrolimus (TRL) on whole-blood lymphocyte function was assessed in vitro as well as in vivo. For the in vitro studies, rat whole blood was incubated with different concentrations of MPA together with CsA or TRL. In vivo, rats (n = 6 per group) were orally treated with 2.5 or 5 mg/kg of mycophenolate mofetil (MMF), either alone or in combination with 5 mg/kg CsA or 4 mg/kg TRL. Blood was obtained before and at different times after dosing. For both in vitro and in vivo studies, mitogen-stimulated whole blood was analyzed by flow cytometry to determine inhibition of expression of lymphocyte proliferation (proliferating cell nuclear antigen, PCNA) and T-cell activation (eg, CD25). Plasma MPA concentrations were measured by HPLC, and whole-blood CsA and TRL concentrations were quantified using LC-MS/MS. In vitro, low concentrations of 250 and 500 nM MPA acted additively with CsA and overadditively with TRL to suppress lymphocyte function, whereas higher MPA concentrations (1000 nM) in these combinations did not further increase inhibition compared with monotherapy with CsA or TRL alone. In vivo, the MPA AUC0-24 showed a dose-dependent increase. CsA and TRL AUC0-24 were not influenced by the MMF dose. Combination therapy increased inhibition of lymphocyte function compared with MMF monotherapy with a pronounced effect on PCNA compared with CD25. Significant differences between 2.5 and 5 mg/kg MMF in the combination groups were observed at 2 or 6 hours after dosing because of the maximal inhibitory effect on PCNA and CD25 expression (P < 0.05, ANOVA). However, in combination with TRL no different effects on the inhibition of CD25 expression were found between the 2 MMF doses. These novel data indicate that measurement of pharmacodynamic parameters of lymphocyte function in whole blood may help to monitor drug combination therapy and provide a rationale for drug reduction to minimize toxicity without compromising efficacy.